These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24596530)

  • 1. Bortezomib-induced painful neuropathy in patients with multiple myeloma.
    Bilińska M; Usnarska-Zubkiewicz L; Pokryszko-Dragan A
    Contemp Oncol (Pozn); 2013; 17(5):421-6. PubMed ID: 24596530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
    Carozzi VA; Renn CL; Bardini M; Fazio G; Chiorazzi A; Meregalli C; Oggioni N; Shanks K; Quartu M; Serra MP; Sala B; Cavaletti G; Dorsey SG
    PLoS One; 2013; 8(9):e72995. PubMed ID: 24069168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma.
    Allegra A; Rizzo V; Innao V; Alibrandi A; Mazzeo A; Leanza R; Terranova C; Gentile L; Girlanda P; Allegra AG; Alonci A; Musolino C
    Arch Med Sci; 2022; 18(3):696-703. PubMed ID: 35591819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Bortezomib-Induced Neurotoxicity.
    Meregalli C
    Toxics; 2015 Jul; 3(3):294-303. PubMed ID: 29051465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
    Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
    J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.
    Bechakra M; Nieuwenhoff MD; van Rosmalen J; Groeneveld GJ; Scheltens-de Boer M; Sonneveld P; van Doorn PA; de Zeeuw CI; Jongen JL
    Mol Pain; 2018; 14():1744806918797042. PubMed ID: 30152246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy.
    Ludman T; Melemedjian OK
    Mol Pain; 2019; 15():1744806919850043. PubMed ID: 31041875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
    Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
    Argyriou AA; Iconomou G; Kalofonos HP
    Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α.
    Zhao W; Wang W; Li X; Liu Y; Gao H; Jiang Y; Wang Y
    Ann Hematol; 2019 Dec; 98(12):2793-2803. PubMed ID: 31650289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a rat model of bortezomib-induced painful neuropathy.
    Duggett NA; Flatters SJL
    Br J Pharmacol; 2017 Dec; 174(24):4812-4825. PubMed ID: 28972650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
    Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
    Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M
    Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing treatment-related peripheral neuropathy in patients with multiple myeloma.
    Grammatico S; Cesini L; Petrucci MT
    Blood Lymphat Cancer; 2016; 6():37-47. PubMed ID: 31360079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
    Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2019; 18():1534735419888584. PubMed ID: 31868025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.